Maharashtra FDA Cancels Cipla Pune Warehouse Drug Licences Over Regulatory Violations
The Maharashtra Food and Drug Administration (FDA) has cancelled the drug sale and distribution licences of Cipla Pharma Life Sciences Ltd's warehouse in Wadki, Pune, following alleged violations. These include misbranding of Reactin Plus, a Schedule H prescription medicine, improper storage, record-keeping deficiencies, and handling of expired drugs. The action was taken after fresh proceedings complying with Bombay High Court directions, including a show-cause notice, company response, and personal hearing. The FDA emphasized ensuring medicine safety and regulatory compliance throughout the supply chain.
First-hand measurement across 7 sources
We measured how 7 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (47/100). Lens Score 58/100.
Outlets measured: indiatoday, moneycontrol, freepressjournal, indianexpress, thetelegraph, freepressjournal, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (48–50/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 2 Oct, 01:53 pm. Other outlets followed.